

The State of the Science of HEMATOPOIETIC STEM CELL TREATMENT AND DISABILITY

A Virtual Workshop

November 15, 2021 10 AM-4:30 PM ET

The National Academies of Academies of Academies

Planning Committee Members

Sara Rosenbaum (Chair), George Washington University
Frederick R. Appelbaum, Fred Hutchinson Cancer Research Center
Margaret Bevans, National Heart, Lung and Blood Institute, National
Institutes of Health

Cynthia E. Dunbar, National Heart, Lung, and Blood Institute,

National Institutes of Health

Mary M. Horowitz, Center for International Blood and Marrow Transplant Research

Leslie S. Kean, Harvard Medical School

David T. Scadden, Massachusetts General Hospital

Alexis A. Thompson, Northwestern University

Sponsor

U.S. Social Security
Administration

National Academies
Staff: Laura Aiuppa,
Adrienne Formentos,
Rukshana Gupta,
Sharyl Nass

Statement of Task

- The workshop examines disability associated with stem cell treatments, specifically hematopoietic stem cell transplant. The focus is on functional outcomes for individuals who are recipients of hematopoietic stem cell transplants.
- Invited presentations and panel discussions, key topics: defining what is hematopoietic stem cell transplant; characteristics of patient populations; treatment complications and outcomes; consequences of disabling conditions and transplantation on functioning; and interventions affecting post-transplant functioning.

Agenda

- Welcome, Workshop Overview and Sponsor Remarks
- Session 1: Hematopoietic Stem Cell Treatment and Disability in the United States
- Session 2: Late Effects of Hematopoietic Stem Cell Treatment
- Lunch Break
- Session 3: Hematopoietic Stem Cell Treatment Survivorship
- Session 4: The Future Outlook for Stem Cell Treatment and Disability
- Concluding Remarks

We welcome you to submit questions using the discussion box below the Webinar livestream.